Key regions: United Kingdom, Canada, Japan, Europe, China
Qatar, a small country in the Middle East, has been witnessing a steady growth in the dermatological drugs market over the past few years.
Customer preferences: The demand for dermatological drugs in Qatar is largely driven by the increasing prevalence of skin diseases such as eczema, psoriasis, and skin cancer. The country's hot and humid climate also contributes to the high incidence of skin disorders. Moreover, the preference for cosmetic dermatology procedures such as Botox, dermal fillers, and chemical peels has been on the rise among the affluent population in Qatar.
Trends in the market: The dermatological drugs market in Qatar is expected to witness significant growth in the coming years. This growth can be attributed to the increasing awareness about skin diseases and the availability of advanced treatment options. Moreover, the growing popularity of cosmetic dermatology procedures is also expected to drive the demand for dermatological drugs in the country. The market is also witnessing a shift towards the use of biologics and targeted therapies for the treatment of skin disorders.
Local special circumstances: Qatar's healthcare sector is largely dominated by the public sector, with the government investing heavily in the development of healthcare infrastructure. The country has a high per capita income and a large expatriate population, which has resulted in a high demand for quality healthcare services. The presence of world-class hospitals and clinics in Qatar has also contributed to the growth of the dermatological drugs market in the country.
Underlying macroeconomic factors: Qatar's economy is largely dependent on its oil and gas reserves. However, the country has been diversifying its economy in recent years, with a focus on developing its healthcare sector. The government has been investing heavily in the development of healthcare infrastructure, which has resulted in the growth of the dermatological drugs market in the country. Moreover, the country's high per capita income and large expatriate population have also contributed to the growth of the market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
